Literature DB >> 32284793

The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma.

Antonio Herrera-Merchan1,2, Marta Cuadros1,3, Maria Isabel Rodriguez1,2, Sandra Rodriguez4, Raul Torres4, Marcos Estecio5, Isabel F Coira1,2, Claudia Loidi6, Monica Saiz6, Pedro Carmona-Saez1, Pedro P Medina1,2.   

Abstract

It is increasingly evident that non-coding RNAs play a significant role in tumour development. However, we still have a limited knowledge of the clinical significance of long non-coding RNAs (lncRNAs) in lung cancer. The FENDRR is a long coding RNA (also named FOXF1-AS1) located in the vicinity of the protein-coding gene FOXF1 at 16q24.1 chromosomal region. The present study aimed to define the clinic pathological significance of the long-non-coding RNA FENDRR in lung adenocarcinomas. FENDRR expression measured by quantitative PCR was found significantly downregulated (p<0.001) in lung adenocarcinoma samples in comparison with their normal adjacent tissues (n=70). RNA in situ hybridization (RNA-FISH) corroborated independently the down-regulation of FENDRR. Interestingly, the expression of FENDRR correlated positively (p<0.001) with the expression of its protein-coding neighbor gene FOXF1. Additionally, FOXF1 expression was also found downregulated in adenocarcinomas compared to normal samples (p<0.001) and its expression was significantly correlated with overall survival alone (p=0.003) or in combination with FENDRR expression (p=0.01). In conclusion, our data support that FENDRR and FOXF1 expression is decreased in lung adenocarcinoma and should be considered as new potential diagnostic/prognosis biomarkers. Copyright:
© 2017 Herrera-Merchan et al.

Entities:  

Keywords:  FENDRR; FOXF1; lncRNA; lung cancer; methylation

Year:  2017        PMID: 32284793

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  8 in total

1.  Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.

Authors:  Zaiyan Wang; Xiaoning Li; Hao Chen; Li Han; Xiaobin Ji; Qiubo Wang; Li Wei; Yafang Miao; Jing Wang; Jianfeng Mao; Zeming Zhang
Journal:  Med Sci Monit       Date:  2021-05-12

Review 2.  Long Non-Coding RNA FENDRR: Gene Structure, Expression, and Biological Relevance.

Authors:  Przemyslaw Szafranski; Paweł Stankiewicz
Journal:  Genes (Basel)       Date:  2021-01-27       Impact factor: 4.141

3.  Autophagy-Related Long Non-coding RNA Is a Prognostic Indicator for Bladder Cancer.

Authors:  Jiaming Wan; Cheng Guo; Hongpeng Fang; Zhongye Xu; Yongwei Hu; Yun Luo
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

4.  Prognostic and Predicted Significance of FENDRR in Colon and Rectum Adenocarcinoma.

Authors:  Fan Yang; Siyu Sun; Fei Yang
Journal:  Front Oncol       Date:  2021-09-21       Impact factor: 6.244

5.  LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma.

Authors:  Zhichao Lin; Wenhai Huang; Yongsheng Yi; Dongbing Li; Zehua Xie; Zumei Li; Min Ye
Journal:  Int J Gen Med       Date:  2021-11-20

6.  LncRNA FENDRR Servers as a Possible Marker of Essential Hypertension and Regulates Human Umbilical Vein Endothelial Cells Dysfunction via miR-423-5p/Nox4 Axis.

Authors:  Xiaojian Zhao; Chen Wang; Min Liu; Fansen Meng; Kai Liu
Journal:  Int J Gen Med       Date:  2022-03-05

7.  Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Authors:  Beatriz Andrea Otálora-Otálora; Daniel Alejandro Osuna-Garzón; Michael Steven Carvajal-Parra; Alejandra Cañas; Martín Montecino; Liliana López-Kleine; Adriana Rojas
Journal:  Biology (Basel)       Date:  2022-07-20

8.  Highly Expressed FOXF1 Inhibit Non-Small-Cell Lung Cancer Growth via Inducing Tumor Suppressor and G1-Phase Cell-Cycle Arrest.

Authors:  Chia-Yu Wu; Chun-Hao Chan; Navneet Kumar Dubey; Hong-Jian Wei; Jui-Hua Lu; Chun-Chao Chang; Hsin-Chung Cheng; Keng-Liang Ou; Win-Ping Deng
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.